reason report
bottom line appreci bdx overal investor
percept safer invest given diversifi sale mix
bard ep synergi cushion prefer name
large-cap med-tech univers offer upsid potenti thu
stay mp rate stock shrug lutonix drug-coated-
balloon dcb concern howev still think uncertainti around
import growth driver limit upsid potenti number
especi below-the-kne btk indic unlik
near-term management remain confid underli growth
part biz counter potenti dcb impact keep
grower top-lin dd grower bottom-lin near-
to-intermedi term nonetheless one import upsid lever
remov make harder argu bigger multipl expans
alreadi give credit pt pt unchang assum
trade slightli large-cap med-tech diversifi peer
vs peer average reflect turn multipl expans vs
current slightli lower ep
 lower tax off-set ep beat consensu
deliv sale came consensu
ahead consensu org revenue growth y/i
cc miss us/consensu reflect anticip
acceler turn biz segment deliv msd
growth bd life scienc cc largest underperform
bd medic cc in-lin bd intervent cc
outperform rel our/consensu expect bd medic
driven medic manag solut
system bd life scienc bioscienc unit primari driver
weak came better expect drive intervent
upsid led strength part portfolio wavelinq covera
venovo exclud dcb impact pi grew hsd intervent
grew y/i cc gm consensu
vs driven unfavor fx mix incl less dcb sale
ebita mgn miss consensu ultim
better expect interest income/expens lower-than-
expect tax rate off-set adj ep beat consensu
svb leerink
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million bd stand-alone onward new co inclus bcr oper deal close
pleas refer page import disclosur price chart analyst certif
organ cc guid reiter -- -big
expect management reiter org cc revenue growth incl bard revenue
cc toward low-end guidanc
rang given impact dcb market pressur call
reduct sale balanc headwind
 delay lutonix btk timelin headwind segment
full-year guidanc contempl medic revenue growth cc
driven md life scienc revenue growth cc
led diagnost system bioscienc intervent revenue
growth cc sever new product unfold wavelinq
venovo covera partial off-set dcb impact management
re-affirmed strong acceler similar
fx abat new product gain steam revenue synergi ramp management
express confid abil remain grower
without provid formal guidanc strength underli busi
new product launch counter dcb headwind
lower interest/oth off-set higher tax adj
ep guidanc impli y/i report y/
cc ex bp fx headwind gm ebita margin unchang
respect gm primarili impact fx
improv well ebita margin improv fx
abat cost synergi ramp sg leverag unfold recal
factor contempl guidanc includ headwind relat
paclitaxel-co devic lutonix headwind resin
raw materi flu impact tariff
 divestitur headwind management expect interest/
net vs prior tax rate still
expect unchang would impli signific step
tax rate vs encouragingli management remain confid
dd earn growth
btk delay pma approv management believ dcb market
pressur persist continu assum sale
reduct carri forward lutonix
consist check bd see surgeon take precaut
dial back util paclitaxel product management believ fda need
come statement indic benefit outweigh risk
order begin see market rebound -- -and even recoveri
could take year regard lutonix btk pma submiss
fda notifi pma approv clinic
evid provid bd plan work fda path forward
submiss includ need potenti provid addit clinic
data result approv timelin delay concret
timelin expect approv management acknowledg
dcb undoubtedli headwind remain confid
part pi portfolio busi larg off-set
lutonix declin bd total revenu help compani
sustain top-lin growth profil near-to-intermedi term
part pi revenue reflect revenue pressur due
uncertainti around long take market rebound/
improv time btk fda approv us commerci
longer expect
diabet patch delay bd partner parti
work strateg option bd withdrew fda
applic base intricaci product comprehens
feedback receiv fda management indic engag
third parti partner work strateg option thu
approv timelin extend
continu posit bia ep step-up bcr transact provid
context volatil market bdx diversifi sale mix bcr-relat ep synergi
cushion may view rel safer invest potenti limit stock downsid
howev name large-cap med-tech univers prefer
offer upsid potenti pt assum trade premium large-
cap med-tech diversifi peer given above-averag ep growth potenti get
construct name like greater convict upsid bcr synergi forecast order
argu bigger multipl premium large-cap med-tech diversifi vs current
pt think compar larg diversifi
med-tech peer group given exposur across medic technolog life scienc
peer group includ trade ep among
group rev/ep growth profil average correspond
price-to-earnings multipl meanwhil cc revenue and/or ep growth profil
correspond price-to-earnings multipl think trade
premium lower bound rang discount upper bound
appli price-to-earnings ep get us pt
risk valuat includ accret estim bcr prove overli conserv
aggress fx volatil signific exposur emerg market revenue growth
volatil slower-than-anticip uptak compani diagnost
becton dickinson compani result glanc
dollar million except ep
margin sale
compani report factset consensu svb leerink llc estim
becton dickinson compani annual outlook
dollar million except ep
total interest incom net
revenu
compani report svb leerink llc estim
becton dickinson compani annual outlook
dollar million except ep
compani report svb leerink llc estim
bp op mgn expans
bp op mgn expans
bp op mgn expans
dollar million except per share data
product sold ex-amort ex-item
sell administr expens
research develop expens
total oper cost expens
fx neutral total oper cost expens
total interest incom net
alloc prefer dividend
gaap ep avail common sharehold dilut
sell administr
research develop
total oper cost expens
sell administr
research develop
total oper cost expens
compani report svb leerink llc estim
sale report repres report revenue growth rate without exclus big step-up inclus bcr oper
pro-forma sale growth calcul base compar rev inclus bcr adjust fx impact
reflect report revenue growth bd stand-alone ex bcr
onward includ bcr oper report revenu
comment line item note guidanc commentari
becton dickinson compani revenu model new co bd bcr
dollar million except per share data
note model reflect bcr combin sale
becton dickinson compani revenu model new co bd bcr
dollar million except per share data
note model reflect bcr combin sale
souc compani report svb leerink llc estim number may due round
